Sionna Therapeutics (NASDAQ:SION) Cut to Hold at Lifesci Capital

Sionna Therapeutics (NASDAQ:SION) was downgraded by Lifesci Capital from a “strong-buy” rating to a “hold” rating in a research report issued to clients and investors on Monday,Zacks.com reports.

A number of other research firms also recently weighed in on SION. Stifel Nicolaus restated a “hold” rating and issued a $7.00 price target on shares of Sionna Therapeutics in a research note on Monday. Wedbush cut Sionna Therapeutics from an “outperform” rating to a “neutral” rating and set a $5.00 price objective for the company. in a research report on Monday. Weiss Ratings reissued a “sell (d-)” rating on shares of Sionna Therapeutics in a report on Wednesday, August 5th. Freedom Capital cut shares of Sionna Therapeutics from a “strong-buy” rating to a “hold” rating in a research note on Wednesday, May 20th. Finally, Citizens Jmp downgraded shares of Sionna Therapeutics from an “outperform” rating to a “market perform” rating in a report on Monday. One investment analyst has rated the stock with a Buy rating, eleven have issued a Hold rating and one has issued a Sell rating to the stock. According to MarketBeat, the company presently has a consensus rating of “Hold” and an average target price of $42.22.

Sionna Therapeutics Stock Up 13.3%

Shares of NASDAQ:SION opened at $5.10 on Monday. The company has a market cap of $230.58 million, a P/E ratio of -2.34 and a beta of 1.32. Sionna Therapeutics has a 52 week low of $4.01 and a 52 week high of $54.97. The company has a 50-day moving average price of $40.99 and a 200 day moving average price of $39.92.

Sionna Therapeutics (NASDAQ:SION) last released its earnings results on Thursday, August 6th. The company reported ($0.66) earnings per share (EPS) for the quarter, missing the consensus estimate of ($0.64) by ($0.02). Analysts expect that Sionna Therapeutics will post -2.66 EPS for the current year.

Insider Activity at Sionna Therapeutics

In other Sionna Therapeutics news, Director Peter A. Thompson sold 115,844 shares of the business’s stock in a transaction on Tuesday, June 30th. The stock was sold at an average price of $45.50, for a total transaction of $5,270,902.00. Following the sale, the director directly owned 2,555,877 shares in the company, valued at approximately $116,292,403.50. The trade was a 4.34% decrease in their ownership of the stock. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which can be accessed through this link. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Also, Director Orbimed Advisors Llc sold 115,844 shares of the company’s stock in a transaction on Tuesday, June 30th. The shares were sold at an average price of $45.50, for a total value of $5,270,902.00. Following the completion of the sale, the director directly owned 2,555,877 shares in the company, valued at $116,292,403.50. This trade represents a 4.34% decrease in their position. The disclosure for this sale is available in the SEC filing. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Insiders sold a total of 403,726 shares of company stock valued at $18,259,354 over the last ninety days. 5.10% of the stock is currently owned by company insiders.

Institutional Investors Weigh In On Sionna Therapeutics

Institutional investors and hedge funds have recently made changes to their positions in the business. BlackRock Inc. acquired a new stake in Sionna Therapeutics in the 2nd quarter valued at about $64,875,000. Deutsche Bank AG purchased a new position in Sionna Therapeutics during the 2nd quarter valued at about $2,347,000. Mitsubishi UFJ Asset Management Co. Ltd. acquired a new position in Sionna Therapeutics during the second quarter worth about $44,000. Bank of New York Mellon Corp purchased a new stake in shares of Sionna Therapeutics in the second quarter valued at about $1,829,000. Finally, State of Wyoming acquired a new stake in shares of Sionna Therapeutics in the second quarter valued at approximately $35,000.

More Sionna Therapeutics News

Here are the key news stories impacting Sionna Therapeutics this week:

• Negative Sentiment: SION-719 failed its Phase 2 primary endpoint. The experimental cystic-fibrosis treatment did not produce the expected improvement, prompting Sionna to discontinue development of SION-719 as an add-on therapy. The failure eliminates the company’s principal near-term clinical catalyst and raises uncertainty about the value of its broader pipeline. Sionna Therapeutics Halts Lead Cystic Fibrosis Drug After Phase 2 Failure
• Negative Sentiment: The stock dropped roughly 90% to a record low. The magnitude of the decline reflects investors’ reassessment of Sionna’s prospects following the unexpected trial miss and the loss of its lead drug program. Trading volume was also unusually heavy compared with the company’s average. Sionna Therapeutics stock falls 92% after SION-719 trial failure
• Negative Sentiment: Analysts cut their ratings after the clinical setback. BTIG and Guggenheim moved from “buy” to “neutral,” while Raymond James, Citizens JMP and Wedbush also reduced their ratings. Wedbush and RBC set approximately $5 price targets, signaling limited expected upside at current levels. Sionna Discontinues Cystic Fibrosis Drug Following Unfavorable Data
• Neutral Sentiment: Sionna reported mixed results from two cystic-fibrosis programs and plans to refocus its pipeline. However, the company has not yet identified a replacement asset with comparable clinical maturity, leaving its future strategy and financing needs uncertain. Sionna Reports Mixed Trial Results and Refocuses CF Pipeline
• Neutral Sentiment: The failure benefits rival Vertex Pharmaceuticals. Sionna’s unsuccessful trial removes a potential competitor to Vertex’s established cystic-fibrosis franchise, which explains why Vertex shares rose as Sionna’s stock declined. Vertex Shares Rise as Rival Sionna Trial Fails

Sionna Therapeutics Company Profile

Sionna Therapeutics is a clinical-stage biotechnology company dedicated to developing next-generation RNA therapeutics for oncology and immunology indications. Leveraging proprietary lipid nanoparticle and coacervate delivery technologies, the company aims to overcome key challenges associated with stability, targeting and immune activation that have historically limited the clinical performance of mRNA-based medicines. Its strategic focus spans both solid tumors and hematological malignancies, as well as selected autoimmune disorders, reflecting a broad ambition to harness the power of messenger RNA in diverse therapeutic areas.

At the heart of Sionna’s approach is a platform that combines optimized ionizable lipids with bespoke surface chemistries to enhance payload delivery, intracellular release and endosomal escape.